Thermo Fisher Scientific Inc.

BMV:TMO * Stock Report

Market Cap: Mex$4.0t

Thermo Fisher Scientific Valuation

Is TMO * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TMO * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TMO * (MX$10530.33) is trading below our estimate of fair value (MX$12835.86)

Significantly Below Fair Value: TMO * is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TMO *?

Key metric: As TMO * is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for TMO *. This is calculated by dividing TMO *'s market cap by their current earnings.
What is TMO *'s PE Ratio?
PE Ratio32x
EarningsUS$6.14b
Market CapUS$196.32b

Price to Earnings Ratio vs Peers

How does TMO *'s PE Ratio compare to its peers?

The above table shows the PE ratio for TMO * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average40.6x
DHR Danaher
43.3x14.0%US$170.3b
A Agilent Technologies
27.2x4.1%US$38.5b
LONN Lonza Group
65.7x23.9%CHF 37.7b
IQV IQVIA Holdings
26.1x13.8%US$36.6b
TMO * Thermo Fisher Scientific
32x11.5%Mex$196.3b

Price-To-Earnings vs Peers: TMO * is good value based on its Price-To-Earnings Ratio (32x) compared to the peer average (40.6x).

Price to Earnings Ratio vs Industry

How does TMO *'s PE Ratio compare vs other companies in the Global Life Sciences Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies12PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: TMO * is good value based on its Price-To-Earnings Ratio (32x) compared to the Global Life Sciences industry average (35.6x).

Price to Earnings Ratio vs Fair Ratio

What is TMO *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TMO * PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio32x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate TMO *'s Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TMO * forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentMex$10,530.33
Mex$13,349.47
+26.8%
5.8%Mex$15,657.46Mex$11,946.21n/a28
Nov ’25Mex$11,193.08
Mex$13,144.15
+17.4%
5.5%Mex$15,362.78Mex$12,017.82n/a27
Oct ’25Mex$12,088.95
Mex$12,789.35
+5.8%
5.9%Mex$15,043.32Mex$11,081.46n/a26
Sep ’25Mex$11,967.00
Mex$12,462.21
+4.1%
4.6%Mex$13,596.38Mex$11,133.27n/a25
Aug ’25Mex$11,459.07
Mex$11,862.50
+3.5%
4.4%Mex$12,708.71Mex$10,606.24n/a25
Jul ’25Mex$9,960.00
Mex$11,577.14
+16.2%
4.5%Mex$12,464.65Mex$10,181.61n/a25
Jun ’25Mex$9,600.00
Mex$10,470.56
+9.1%
4.5%Mex$11,297.03Mex$9,227.86n/a25
May ’25Mex$9,760.00
Mex$10,626.82
+8.9%
4.8%Mex$11,521.05Mex$9,410.84n/a26
Apr ’25n/a
Mex$10,095.72
0%
5.5%Mex$11,396.08Mex$8,753.26n/a26
Mar ’25Mex$9,848.06
Mex$10,193.13
+3.5%
5.6%Mex$11,521.59Mex$8,849.67n/a25
Feb ’25Mex$9,440.00
Mex$9,996.35
+5.9%
5.8%Mex$11,106.23Mex$8,884.98n/a23
Jan ’25Mex$9,052.27
Mex$9,295.64
+2.7%
9.4%Mex$10,867.33Mex$7,386.39n/a25
Dec ’24Mex$8,509.35
Mex$9,294.98
+9.2%
8.8%Mex$11,110.91Mex$7,611.41n/a23
Nov ’24Mex$7,900.00
Mex$9,524.16
+20.6%
9.2%Mex$11,310.81Mex$7,748.35Mex$11,193.0823
Oct ’24Mex$8,844.40
Mex$10,919.41
+23.5%
6.3%Mex$12,165.75Mex$9,128.70Mex$12,088.9524
Sep ’24Mex$9,520.40
Mex$10,500.00
+10.3%
6.2%Mex$11,611.35Mex$8,712.70Mex$11,967.0024
Aug ’24Mex$9,220.26
Mex$10,517.56
+14.1%
6.2%Mex$11,687.59Mex$8,707.09Mex$11,459.0725
Jul ’24Mex$8,790.00
Mex$10,763.01
+22.4%
7.2%Mex$11,991.42Mex$8,650.95Mex$9,960.0024
Jun ’24Mex$9,139.00
Mex$11,038.80
+20.8%
7.2%Mex$12,287.38Mex$8,864.47Mex$9,600.0023
May ’24Mex$10,004.00
Mex$11,493.41
+14.9%
7.2%Mex$12,812.38Mex$9,113.03Mex$9,760.0022
Apr ’24Mex$10,150.11
Mex$12,057.90
+18.8%
7.1%Mex$13,211.66Mex$9,383.81n/a22
Mar ’24Mex$9,787.20
Mex$12,057.90
+23.2%
7.1%Mex$13,211.66Mex$9,383.81Mex$9,848.0622
Feb ’24Mex$10,977.78
Mex$11,814.24
+7.6%
8.5%Mex$13,239.53Mex$9,403.61Mex$9,440.0019
Jan ’24Mex$10,750.00
Mex$12,070.36
+12.3%
8.2%Mex$13,966.24Mex$10,254.93Mex$9,052.2722
Dec ’23Mex$10,747.00
Mex$11,890.54
+10.6%
8.5%Mex$13,808.58Mex$10,139.17Mex$8,509.3520
Nov ’23Mex$10,264.61
Mex$12,169.71
+18.6%
8.8%Mex$14,167.30Mex$10,402.56Mex$7,900.0020

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

ICON

US$17.7b

A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.

ICLR N

US$4,286.08

7D

0%

1Y

-7.7%

CSPC Pharmaceutical Group

HK$69.4b

An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.

1093 N

HK$15.69

7D

0%

1Y

-27.0%

Exact Sciences

US$13.1b

Provides cancer screening and diagnostic test products in the United States and internationally.

EXAS *

US$872.00

7D

0%

1Y

n/a